Cork based ProVascTec is looking to raise €1.1 million to further develop cell therapies for blocked arteries in legs.
The company, which is currently valued at €5.3 million, said this condition leads to up to 800 leg amputations annually in Ireland alone.
It said €450,000 has already been secured from NLC Ventures and Enterprise Ireland.
ProVascTec have chosen the Central Bank of Ireland regulated Spark Crowdfunding platform to raise the balance of the funds.
The company said blocked arteries in lower limbs affects 260 million sufferers worldwide.
It said 40% of them can go on to develop critical limb ischemia (CLI), which it said is a worsened condition of peripheral arterial disease (PAD) and requires medical intervention.
"With the support of our investors, we can combine two established principles, cell therapy and intra-arterial delivery, in a novel configuration offering true innovation to the lives of millions of patients throughout the world from our base in Cork at UCC's Gateway Innovation & Incubation Hub," said Dr Holger Müller, CEO of ProVascTec.
"We are delighted to partner with Spark Crowdfunding to launch our equity crowdfunding campaign. A successful campaign will enable us to accelerate our growth, bringing life-saving treatments far quicker for critical limb ischemia to many millions of patients worldwide," he added.
